Vitrakvi Oral Solution 20mg/mL

Vitrakvi Oral Solution 20mg/mL, from Bayer Pharmaceutical, contains Larotrectinib sulfate (YJ code: 4291071S1028, standard: 2%1mL). This oral solution is a selective inhibitor of tropomyosin receptor kinases (TrkA, TrkB, and TrkC) and is used for the treatment of solid tumors harboring NTRK gene fusions, thereby disrupting critical signaling pathways for tumor growth.